Investigation of possible drug interactions of angiotensin II receptor antagonists used in the treatment of hypertension
DOI:
https://doi.org/10.33448/rsd-v9i7.3682Keywords:
Drug Interactions. Antihypertensives. ARA IIAbstract
Arterial hypertension, consists of a pathology where there is an increase in the physiological levels of blood pressure, there is a therapeutic arsenal available for the treatment of hypertension. this pathology, they present indisputable efficacy, few adverse effects and low toxicity, however they are targets of drug interactions with drugs that present the same site of hepatic microsomal metabolism, which can decrease their therapeutic efficacy. The aim of this research was to analyze the drug interactions of angiotensin II receptor antagonists (ARA II). It is characterized as a documentary research, with a quantitative, retrospective, analytical-discussion approach that uses the Micromedex Solutions® database, to obtain drug interactions. The results show that the drugs that are substrates for the CYP pathway, especially the CYP3A4 and CYP2C9 isoforms are more likely to interact, the drug losartan with the highest number of interactions in this study, presents metabolism with the CYP3A4 and CYP2C9 isoforms, the drugs that have alternative metabolism pathways, tend to have as little interaction as possible. In view of this, ARA II is currently one of the best classes for its treatment, however the use of this class of drugs requires observation by the prescribers and accompanying pharmacists.References
VII Diretriz Brasileira de Hipertensão Arterial: (2016). -Conceituação, Epidemiologia e Prevenção Primária. Arquivos Brasileiros de Cardiologia, 107(3), 1-6.
Alves, N. R., de Menezes, P. D. L., Diniz, J. A., de Souza, F. A. F., de Medeiros Carvalho, P. M., & Tavares, S. M. Q. M. C. (2019). Avaliação das interações medicamentosas entre antihipertensivos e hipoglicemiantes orais/Evaluation of drug interactions between antihypertensive and oral hypoglycemic agents. Revista multidisciplinar e de psicologia, 13(44), 374-392.
Campos, A. M. P., de Castro, C. M. L., da Silva, M. C. P., de Sousa, R. B., & Barros, K. B. N. T. (2019). Atenção farmacêutica na otimização da adesão do tratamento anti-hipertensivo: revisão de literatura. Mostra Científica da Farmácia, 6(1).
Faria, A. L. G., Fais, F. L. B., Ribeiro, J. M., Marialva, R. L. H., Costa, V. D., & Matsutani, G. C. (2019). Avaliação das interações medicamentosas e possíveis efeitos colaterais em pacientes idosos da clínica cardiovascular. Diálogos Interdisciplinares, 8(10), 21-28.
Gomes, A. F., Sousa, I. J. O., de Araújo, S., Moura, A. C. L., Gonçalves, R. L. G., & Amorim, V. R. (2018). Avaliação das possíveis interações medicamentosas de inibidores da HMG-coA-redutase utilizados no tratamento da dislipidemia. Unoesc & Ciência-ACBS, 9(1), 39-44.
Hocum, B. T., White Jr, J. R., Heck, J. W., Thirumaran, R. K., Moyer, N., Newman, R., & Ashcraft, K. (2016). Cytochrome P–450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. American Journal of Health-System Pharmacy, 73(2), 61-67.
Kothari, N., & Ganguly, B (2014). Droga potencial - interações medicamentosas entre medicamentos prescritos para pacientes hipertensos. J Clin Diagn Res. 10(4):308-17
Magro, L., Conforti, A., Del Zotti, F., Leone, R., Iorio, M. L., Meneghelli, I. & Moretti, U. (2008). Identification of severe potential drug-drug interactions using an Italian general-practitioner database. European journal of clinical pharmacology, 64(3), 303-309.
May, M., & Schindler, C (2016). Interações clinicamente e farmacologicamente relevantes de drogas antidiabéticas. Endocrinol Metab.
Passos, V. M. D. A., Assis, T. D., & Barreto, S. M. (2006). Hipertensão arterial no Brasil: estimativa de prevalência a partir de estudos de base populacional. Epidemiologia e serviços de Saúde,15(1), 35-45.
Powers, B., Greene, L., & Balfe, L. (2011). Updates on the treatment of essential hypertension: a summary of AHRQ’s comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors. Journal of Managed Care Pharmacy, 17(8 Supp A), 1-14.
Silva, L. C. D. J., & Ramos, M. E. S. P. (2016). Interação medicamentosa entre fármacos anti-hipertensivos em usuários de bebida alcoólica. Revista Enfermagem Contemporânea, 5(2).
Sivva, D. et al (2015). Avaliação de interações medicamentosas em pacientes hipertensos em um hospital de super-especialidade. Avicena J Med. v.5, p. 29-35.
Tsang, C. T, Man, Y., & Cheung, B (2012). Identificação de pacientes com hipertensão resistente e opções de tratamento clínico. Futuro Cardiol. v.8, p. 837-46.
Zaitune, M. P. D. A., Barros, M. B. D. A., César, C. L. G., Carandina, L., & Goldbaum, M. (2006). Hipertensão arterial em idosos: prevalência, fatores associados e práticas de controle no Município de Campinas, São Paulo, Brasil. Cadernos de Saúde Pública, 22(2), 285-294.
Ziaeian, Boback; Fonarow & Gregg (2017). Statins and the Prevention of Heart Disease. JAMA Cardiology.165 (7), p. 908–909.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
